A novel Phase I/IIa theranostic clinical study exploring the safety profile and efficacy of both 99mTc-RHN001 and 188Re-RHN001 in patients with advanced prostate cancer.
Latest Information Update: 28 Oct 2024
At a glance
- Drugs Rhenium-188-RHN-001-Rhine-Pharma (Primary) ; Technetium-99m-RHN-001-Rhine-Pharma (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms RHINO Trial
- 22 Nov 2024 According to Telix Pharmaceuticals Media release, The RHINO Trial has received both ethics and regulatory approval in South Africa and is being run by NuMeRI's CEO and President, Professor Mike Sathekge, and his team.
- 28 Oct 2024 New trial record